[Purpose] This study aims to clarify the validity of therapeutic angiogenesis using autologous peripheral blood mononuclear cell transplantation (PB-MNC) in patients with critical limb ischemia (CLI). [Subjects and Methods] Eighteen patients who had major amputation despite maximal revascularization therapy and who have been observed more than six months since receiving PB-MNC were enrolled. The collected data included patient characteristic, blood biochemistry, number of CD34 positive cells and platelets, angiographic images, ankle brachial index (ABI), transcutaneous oxygen pressure (tcPO
2), and they were evaluated for correlation between 6 patients with and 12 patients without major amputation. [Results] In patients with major amputation, the levels of C-reactive protein (CRP) continued to be higher, and the levels of ABI and tcPO
2, and the number of transplanted CD34 positive cells and platelets, were lower than those of patients without major amputation. Favorable blood flow of the upperpopliteal arteries, and anterograde flow in two of the infrapopliteal arteries were essential to avoid major amputation. [Conclusions] Therapeutic angiogenesis using PB-MNC was useful for patients with CLI who were managed for infection and who had revascularization of the upperpopliteal arteries and two of the infrapopliteal arteries by endovascular and/or surgical revascularization.
View full abstract